NCT03319121View on ClinicalTrials.gov

The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Non Cardiac Chest Pain
Interventions
DRUG

Empirical therapy group

Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.

DRUG

Guided therapy group

Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.

Trial Locations (1)

16150

Hospitial Universiti Sains Malaysia, Kubang Kerian

All Listed Sponsors
lead

Universiti Sains Malaysia

OTHER

NCT03319121 - The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain | Biotech Hunter | Biotech Hunter